Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. - Wikidata - wikimedia - TriplyDB

Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa.

Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa.

http://www.wikidata.org/entity/Q37216229

about

Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: a bayesian analysis Virologic failure of protease inhibitor-based second-line antiretroviral therapy without resistance in a large HIV treatment program in South Africa Cost-effectiveness of tenofovir instead of zidovudine for use in first-line antiretroviral therapy in settings without virological monitoring Nevirapine- versus lopinavir/ritonavir-based initial therapy for HIV-1 infection among women in Africa: a randomized trial Differential in vitro kinetics of drug resistance mutation acquisition in HIV-1 RT of subtypes B and C Monitoring HIV viral load in resource limited settings: still a matter of debate?High-levels of acquired drug resistance in adult patients failing first-line antiretroviral therapy in a rural HIV treatment programme in KwaZulu-Natal, South Africa Trends in Prevalence of HIV-1 Drug Resistance in a Public Clinic in Maputo, Mozambique Low Incidence of HIV-1C Acquired Drug Resistance 10 Years after Roll-Out of Antiretroviral Therapy in Ethiopia: A Prospective Cohort Study Virological efficacy and emergence of drug resistance in adults on antiretroviral treatment in rural Tanzania.Understanding HIV transmission risk behavior among HIV-infected South Africans receiving antiretroviral therapy: an information--motivation--behavioral skills model analysis.Factors Associated with Virological Non-suppression among HIV-Positive Patients on Antiretroviral Therapy in Uganda, August 2014-July 2015.Occult HIV-1 drug resistance to thymidine analogues following failure of first-line tenofovir combined with a cytosine analogue and nevirapine or efavirenz in sub Saharan Africa: a retrospective multi-centre cohort study.Durable HIV RNA resuppression after virologic failure while remaining on a first-line regimen: a cohort study.One-, two-, and three-class resistance among HIV-infected patients on antiretroviral therapy in private care clinics: Mumbai, India.Deferred modification of antiretroviral regimen following documented treatment failure in Asia: results from the TREAT Asia HIV Observational Database (TAHOD).Patient Characteristics and Treatment Outcome Associated with Protease Inhibitor (PI) use in the Asia-Pacific Region The net cost of incorporating resistance testing into HIV/AIDS treatment in South Africa: a Markov model with primary data.Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa.The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy.Outcomes after virologic failure of first-line ART in South Africa HIV multi-drug resistance at first-line antiretroviral failure and subsequent virological response in Asia Affordable in-house antiretroviral drug resistance assay with good performance in non-subtype B HIV-1.Drug susceptibility and resistance mutations after first-line failure in resource limited settings HIV-1 reverse transcriptase drug-resistance mutations in chronically infected individuals receiving or naïve to HAART in Cameroon.Second-line antiretroviral therapy in a workplace and community-based treatment programme in South Africa: determinants of virological outcome Drug resistance in non-B subtype HIV-1: impact of HIV-1 reverse transcriptase inhibitors.A comparative analysis of HIV drug resistance interpretation based on short reverse transcriptase sequences versus full sequences.Gender-specific risk factors for virologic failure in KwaZulu-Natal: automobile ownership and financial insecurity.Recent developments in hiv treatment and their dissemination in poor countries HIV prevention counseling intervention delivered during routine clinical care reduces HIV risk behavior in HIV-infected South Africans receiving antiretroviral therapy: the Izindlela Zokuphila/Options for Health randomized trial Protease Inhibitor Resistance Is Uncommon in HIV-1 Subtype C Infected Patients on Failing Second-Line Lopinavir/r-Containing Antiretroviral Therapy in South Africa Replicative fitness costs of nonnucleoside reverse transcriptase inhibitor drug resistance mutations on HIV subtype C.Effectiveness of Psycho-Educational Intervention in HIV Patients' Treatment.Efficacy of second-line antiretroviral therapy among people living with HIV/AIDS in Asia: results from the TREAT Asia HIV observational database Pooling strategies to reduce the cost of HIV-1 RNA load monitoring in a resource-limited setting.Impact of drug resistance-associated amino acid changes in HIV-1 subtype C on susceptibility to newer nonnucleoside reverse transcriptase inhibitors.Implementing antiretroviral resistance testing in a primary health care HIV treatment programme in rural KwaZulu-Natal, South Africa: early experiences, achievements and challenges.Laboratory monitoring to guide switching antiretroviral therapy in resource-limited settings: clinical benefits and cost-effectiveness Drug resistance patterns and virus re-suppression among HIV-1 subtype C infected patients receiving non-nucleoside reverse transcriptase inhibitors in South Africa

P2860

Q28478121-1B5AFF16-322F-40D7-9462-D6B6F7CDD64C Q28481468-EB99F627-B455-43ED-8439-9D03E8F429EF Q28482138-E1148569-AC57-4F20-BDB9-E5EFF0E60697 Q28484207-E5F244A9-E9D5-4A80-93A1-D183A1E5B8B0 Q28484213-7C76EE84-2971-4E28-A3F5-BA4D92780618 Q28485511-EC8B1CA8-7FDF-4A38-8C79-94CE3EFBA668 Q28535483-2B979D79-AD20-4D14-874F-D6066788BFC7 Q28546341-47095FC8-1DAD-4FBF-8959-F845FFD5103B Q28550552-C89FFA51-C7BD-4475-9B30-E7E1DA9983DB Q33479343-D6A25F23-B691-476D-8688-A1D0C3D18983 Q33554700-5F5D9AFE-68B8-49AA-AADB-9F12D42EEB7D Q33634625-37E7ECC2-36EC-4A4F-85F4-B2F8A3E49728 Q33647567-97ADD123-4231-44BC-B218-31BCA568A57B Q33805619-CEFCE3B4-A56B-4B46-AE82-BD162FBCD167 Q33807513-32CDF1E1-1A8B-4564-BC23-58A2EF1B89A5 Q33824851-FB1AF34B-9919-422B-91BC-517BB04CFB20 Q33873540-730B3245-ED24-4896-AD00-554693F535F1 Q33901360-2036EB33-194D-4A64-B79D-338F46B5AE2E Q33952538-B6FFBBB2-444F-4F37-B474-2AC49475DD48 Q33959260-DD771AB1-0F76-4B86-B6B2-7C1327C7E513 Q33985234-AA8B4BCD-C73A-4939-AA71-AC479912EDC1 Q34072721-D487728C-4E7C-4B1A-9D7B-C810880085B2 Q34102202-E090F27D-1867-4D63-B4B7-AD9DDA817BC1 Q34106181-39DBF84A-CEF3-4B7B-B350-43C2988EDF16 Q34219941-91AC4FF4-BE9F-4FDB-98BD-E7FE9C9D2AA1 Q34292437-7A1ACC3A-5DF2-4AE3-8BD3-0BF9BA4A9182 Q34303603-2E4E5A5E-4049-45CD-B40C-7D366E6D7299 Q34321402-C1C138FF-2E13-4D7A-A519-A9F0712FE6EA Q34345205-403C2833-1C71-4EDC-8F22-A72BADDB13E1 Q34400513-63D26A22-DC37-40CC-9C90-31EC8A862353 Q34498574-B3A6EEB5-F24D-45F2-9CA4-77403E2A16E2 Q34734833-01C260F4-62F7-42CC-AF51-66D98FE2DFBF Q34933329-17BF954B-321A-45DC-8AEC-5F6EE46729B2 Q34969086-F3F35D44-B668-4DE1-8FF2-A281F69342A0 Q34977431-519EF2CD-C40B-4678-8622-DF932D685FD4 Q35019884-39D4BE8D-F3DA-4937-826B-F39EA9C675D4 Q35105844-D79B3EB1-02EE-4F34-9B49-7BC15191E7C7 Q35114102-E49480EE-2426-484D-9A5E-3C1409FB9D62 Q35217495-BEE89DF9-4BA7-4B3D-A095-BD2A9ACC37F9 Q35217629-DE99633C-7DE3-4F69-BD6D-DF374929FBD9

P2860

Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa.

http://www.wikidata.org/entity/Q37216229

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on May 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Prevalence of HIV-1 drug resis ...... n KwaZulu Natal, South Africa.

@en

Prevalence of HIV-1 drug resis ...... n KwaZulu Natal, South Africa.

@nl

type

label

Prevalence of HIV-1 drug resis ...... n KwaZulu Natal, South Africa.

@en

Prevalence of HIV-1 drug resis ...... n KwaZulu Natal, South Africa.

@nl

prefLabel

Prevalence of HIV-1 drug resis ...... n KwaZulu Natal, South Africa.

@en

Prevalence of HIV-1 drug resis ...... n KwaZulu Natal, South Africa.

@nl

P1433

Q37216229-DF43CAF9-4B27-4906-9A89-7D4451960CD6

P1476

Q37216229-9DA1D57C-F6FF-4B2D-B751-97A6BEE267A0

P2093

Q37216229-1B93C406-AEB9-493B-ADEE-07EBC122C029

Q37216229-24B36BE0-CC01-4633-A547-F3E3630C6C24

Q37216229-3D87A525-66F2-4FCA-8B25-AC7DFAEAF8B6

Q37216229-4A71E6AB-8601-47C7-A216-66700BB3BC28

Q37216229-88AACEE5-A8A4-4A00-B773-A3DB0F915DFC

Q37216229-9758F407-BC39-4C61-B78C-63C2751D05E0

Q37216229-A63C9F21-628A-465F-99C4-FD653706F77E

Q37216229-CA9224AD-8146-44CD-AB57-CB863FFC9898

Q37216229-DE5DAB95-1532-4532-9DE8-CBFC1FB4839B

P2860

Q37216229-02D904A2-8907-4C6F-A5E5-6AAD46C35CF7

Q37216229-1ADD09F4-ECCE-4D21-BBA1-B63B4F0EFE88

Q37216229-22D4B02D-67E5-49AB-AC46-2F92A68B0591

Q37216229-4D2D3B9D-90A0-4F50-AC00-CDEE9FFE3DAF

Q37216229-4E3EDE68-3165-4001-A879-8499A7C046D5

Q37216229-5113089E-2E5C-44E2-88C5-FE6FBB9735EB

Q37216229-6350E307-784C-484C-AF15-9FC13BAB162B

Q37216229-65C726B5-2ABD-4FC1-97B4-5D4CED3EEDFD

Q37216229-757287C7-0D80-4CCF-8303-3A84532206FF

Q37216229-7F50F0E6-A332-4C79-B909-0211D1005F6A

P304

Q37216229-A8C53EB5-7ED0-40B5-AB6F-618FF29D6D21

P31

Q37216229-B32F2F61-AE53-4CD8-A87B-7715A39DC2A0

P356

Q37216229-E9217FD4-2382-4ED0-B17E-D356BC72AEFA

P407

Q37216229-4266ADDA-E7AE-4E64-B4FB-44476460A7C3

P433

Q37216229-85C68069-E785-411E-B944-5B4D535549B7

P478

Q37216229-0069FD21-CF25-4229-BF7E-FDB03B4BA31E

P50

Q37216229-5E09DF4A-3F1B-4E0A-B785-28DEB7611211

Q37216229-6AA41321-E49C-4247-9E0E-1F5E69DD0859

Q37216229-A5EA122C-AE6E-4159-BCAB-D1DD475F302A

Q37216229-B6415298-6973-42B0-821F-81F2E1BC4B39

Q37216229-EED3BECF-3FA8-48CC-929A-8F6E679CD6E6

P577

Q37216229-9BD39CBA-FBA7-4793-9812-B49B8D3816B0

P5875

Q37216229-A0F3AC81-497B-44C4-8056-BFC8400CF534

P698

Q37216229-8B99C044-B99C-4203-A3C3-DC9CC0790E19

P921

Q37216229-12D92A40-0D71-4A88-BC43-F3199A04685F

Q37216229-9765EE76-B9E7-4F15-93B5-72CD87C919C4

Q37216229-B649DF6F-779B-4C98-A69B-392652E2003E

Q37216229-CB14CE98-33D9-4052-99F9-CAC2772E5C71

P932

Q37216229-3E68DC20-96F5-4933-AC27-7E9CD0DD4ACF

P356

P1433

Clinical Infectious Diseases

P1476

Prevalence of HIV-1 drug resis ...... n KwaZulu Natal, South Africa.

@en

P2093

Daniel R Kuritzkes

http://www.w3.org/2001/XMLSchema#string

Helga Holst

http://www.w3.org/2001/XMLSchema#string

Henry Sunpath

http://www.w3.org/2001/XMLSchema#string

Jane Hampton

http://www.w3.org/2001/XMLSchema#string

Kofi Koranteng-Apeagyei

http://www.w3.org/2001/XMLSchema#string

Michelle Gordon

http://www.w3.org/2001/XMLSchema#string

South Africa Resistance Cohort Study Team

http://www.w3.org/2001/XMLSchema#string

Steve Carpenter

http://www.w3.org/2001/XMLSchema#string

Zhigang Lu

http://www.w3.org/2001/XMLSchema#string

P2860

Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration

Genetic divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against nonnucleoside inhibitors of RT.

Testing genotypic and phenotypic resistance in human immunodeficiency virus type 1 isolates of clade B and other clades from children failing antiretroviral therapy.

High prevalence of the K65R mutation in human immunodeficiency virus type 1 subtype C isolates from infected patients in Botswana treated with didanosine-based regimens.

Paradoxes of adherence and drug resistance to HIV antiretroviral therapy.

Extending antiretroviral therapy to resource-poor settings: implications for drug resistance.

What policymakers should know about drug resistance and adherence in the context of scaling-up treatment of HIV infection.

Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa.

High prevalence of antiretroviral resistance in treated Ugandans infected with non-subtype B human immunodeficiency virus type 1.

Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance.

P304

1589-1597

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1086/587109

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

46

http://www.w3.org/2001/XMLSchema#string

P50

Bruce D. Walker

Vincent C Marconi

Douglas T. Ross

P577

2008-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5434173

http://www.w3.org/2001/XMLSchema#string

P698

18419495

http://www.w3.org/2001/XMLSchema#string

P921

Aafrikaa Kibbaa

antiretroviral drug

P932

2692213

http://www.w3.org/2001/XMLSchema#string